A detailed history of Boothbay Fund Management, LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 34,710 shares of XERS stock, worth $118,014. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,710
Previous 34,710 -0.0%
Holding current value
$118,014
Previous $78,000 25.64%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.7 - $2.45 $14,433 - $20,800
-8,490 Reduced 19.65%
34,710 $78,000
Q1 2024

May 15, 2024

BUY
$2.04 - $3.22 $88,128 - $139,104
43,200 New
43,200 $95,000
Q2 2022

Aug 15, 2022

SELL
$1.48 - $2.64 $47,972 - $85,572
-32,414 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$2.0 - $2.87 $3,968 - $5,694
1,984 Added 6.52%
32,414 $83,000
Q4 2021

Feb 14, 2022

BUY
$1.8 - $2.93 $54,774 - $89,159
30,430 New
30,430 $89,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $462M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.